Genomic Health Confident in Gaining Ground in Prostate Cancer Testing as It Preps Liquid Biopsy | GenomeWeb

NEW YORK (GenomeWeb) – Genomic Health officials this week discussed the firm's efforts aimed at gaining reimbursement for its Oncotype DX prostate cancer test and discussed plans for its highly anticipated liquid biopsy offering, which is expected to launch later this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.